These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 21324610)

  • 1. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.
    Miralbell R; Roberts SA; Zubizarreta E; Hendry JH
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e17-24. PubMed ID: 21324610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
    Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
    Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What hypofractionated protocols should be tested for prostate cancer?
    Fowler JF; Ritter MA; Chappell RJ; Brenner DJ
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1093-104. PubMed ID: 12829147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability of α/β ratios for prostate cancer with the fractionation schedule: caution against using the linear-quadratic model for hypofractionated radiotherapy.
    Cui M; Gao XS; Li X; Ma M; Qi X; Shibamoto Y
    Radiat Oncol; 2022 Mar; 17(1):54. PubMed ID: 35303922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials.
    Vogelius IR; Bentzen SM
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):858-865. PubMed ID: 29485063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionation for clinically localized prostate cancer.
    Hickey BE; James ML; Daly T; Soh FY; Jeffery M
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical estimation of α/β values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy.
    Datta NR; Stutz E; Rogers S; Bodis S
    Acta Oncol; 2018 Jul; 57(7):883-894. PubMed ID: 29405785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial.
    de Vries KC; Wortel RC; Oomen-de Hoop E; Heemsbergen WD; Pos FJ; Incrocci L
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):108-115. PubMed ID: 31593756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
    Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
    Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In regard to Miralbell et al. Re: Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha/beta=1.4 (0.9-2.2) Gy.
    Pedicini P; Caivano R; Strigari L; Benassi M; Fiorentino A; Fusco V
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):10-1. PubMed ID: 23237001
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
    Brand DH; Brüningk SC; Wilkins A; Fernandez K; Naismith O; Gao A; Syndikus I; Dearnaley DP; Tree AC; van As N; Hall E; Gulliford S;
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):596-608. PubMed ID: 33412260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer dose-response, fractionation sensitivity and repopulation parameters evaluation from 25 international radiotherapy outcome data sets.
    Tamponi M; Gabriele D; Maggio A; Stasi M; Meloni GB; Conti M; Gabriele P
    Br J Radiol; 2019 Jun; 92(1098):20180823. PubMed ID: 31017457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deriving prostate alpha-beta ratio using carefully matched groups, long follow-up and the phoenix definition of biochemical failure.
    Shaffer R; Pickles T; Lee R; Moiseenko V
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1029-36. PubMed ID: 20558012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is alpha/beta for prostate tumors really low?
    Fowler J; Chappell R; Ritter M
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):1021-31. PubMed ID: 11429230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The minimal FLASH sparing effect needed to compensate the increase of radiobiological damage due to hypofractionation for late-reacting tissues.
    Böhlen TT; Germond JF; Bourhis J; Bailat C; Bochud F; Moeckli R
    Med Phys; 2022 Dec; 49(12):7672-7682. PubMed ID: 35933554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.